Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine

Cellular Immunology

Volumn 213, Issue 1, 2001, Pages 4-13

  Orentas, Rimas J ^a   Schauer, Dennis ^a   Bin, Qian ^a   Johnson, Bryon D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cancer vaccine; Cell fusion; Cytotoxic tlymphocyte; Dendritic cells; Neuroblastoma

Indexed keywords

CANCER VACCINE; TUMOR VACCINE;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CELL SURFACE; DENDRITIC CELL; ELECTROFUSION (CELL); IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNOLOGY;

ANIMALIA; MURINAE;

EID: 0035841263     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.2001.1864     Document Type: Article

References (25)

1. Neuroblastoma
2. The dendritic cell system and its role in immunogenicity
3. Dendritic cells: Unique leukocyte populations which control the primary immune response
4. Expression of cytokine mRNA in murine splenic dendritic cells and better induction of T cell-derived cytokines by dendritic cells than by macrophages during in vitro costimulation assay using specific antigens
5. Functional expression of the costimulatory molecule B7/BB1 on murine dendritic cell populations
6. Activation of human dendritic cells through CD40 cross-linking
7. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
8. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity
9. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
10. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
11. +T lymphocytes respond to dendritic cells exposed to b3a2 containing cell lysates
12. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells
13. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
14. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
15. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected
16. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
17. Detection and quantitation of cell-cell electrofusion products by flow cytometry
18. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes
19. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
20. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
21. Retropertitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response
22. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ
23. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
24. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity
25. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration